

A SAS® Program for the Computation of Seroconversion Rates in a Prospective Study of HIV Discordant Couples in Lusaka, Zambia

Ilene Brill, University of Alabama at Birmingham, Birmingham, AL
Maurizio Macaluso, University of Alabama at Birmingham, Birmingham, AL
Jareen K. Meinzen-Derr, Center for Pediatric Research, Norfolk, VA
Susan Allen, University of Alabama at Birmingham, Birmingham, AL

ABSTRACT

A SAS program was designed to monitor HIV seroconversion (i.e., the transition from HIV seronegative to HIV seropositive status, indicating a new infection) in a prospective cohort of HIV discordant (one partner HIV+, the other HIV-) cohabiting couples in Lusaka, Zambia. Couples are followed up every three months. The investigator was interested in computing seroconversion rates during specified time intervals: 1) during each 3-month follow-up interval, 2) during progressively longer periods (e.g, 0-6 months, 0-9 months, etc.) and 3) for specified combinations of these same three month intervals (e.g., from month 6 to month 12). The program consists of three macros implementing the three calculations described above. Total person months and number of seroconvertors are calculated by sex and for both sexes combined among at-risk (i.e., HIV-) subjects. Seroconversion rates are expressed as the number of seroconvertors per 100 person-years of follow-up. Confidence intervals for seroconversion rates are calculated using the GAMINV function in SAS to determine the upper and lower limits for the number of seroconvertors (which is assumed to follow a Poisson distribution), then divided by the total person months of follow-up. This program can be easily modified to calculate incidence rates of other outcomes and can accommodate variable follow-up intervals.

INTRODUCTION

The Zambia-UAB HIV (Human Immunodeficiency Virus) Research Project is a prospective follow-up study of HIV discordant (one partner HIV+, the other HIV-) cohabiting heterosexual couples in Lusaka, Zambia.¹ The objectives of this study are 1) to determine whether voluntary HIV testing and counseling increases condom use and decreases the incidence of HIV in initially HIV- partners, and 2) to assess self-reported sexual behavior (including condom use) and biological markers of exposure in these couples.¹⁻³ To identify and recruit eligible couples, the project established a center for voluntary HIV counseling and confidential serological testing for cohabiting couples in Lusaka, Zambia. Eligibility criteria included being engaged in a sexual relationship and cohabiting for at least six months.¹ Age at recruitment must have been ≤ 48 years for a woman and ≤ 65 years for a man.¹ Eligible recruits had to reside in Lusaka, Zambia, be free of overt psychiatric disturbance and willing to complete required procedures.

Assessment of serologic HIV status was made at entry and during follow up by employing a rapid screening assay followed by a confirmatory assay when indicated (i.e., to confirm an initially positive test, or to confirm the seronegative status of the partner of a seropositive subject).¹

When HIV seroconversion (i.e., the transition from HIV seronegative to HIV seropositive status) was detected, DNA sequencing was used to confirm within-couple transmission, i.e., that the virus transmitted to the seroconverter was the virus hosted by the HIV+ partner.¹ Follow-up data were available for 1011 eligible couples. The earliest baseline visit date was on February 6, 1995 and the last follow-up visit attended was on November 30, 1998. The maximum length of follow-up for HIV- subjects for these analyses was 45 months; 107 HIV seroconversions occurred during the study period of which 94 had DNA sequencing data available.¹ Within-couple transmission was confirmed for 82 (87%) of 94 seroconverting couples with DNA sequencing data, while the other 12 HIV seroconvertors were assumed to have acquired HIV from an HIV+ partner who was not a member of the discordant couple.¹ The 13 HIV seroconvertors with missing DNA sequencing data were assumed to be epidemiologically linked for the purpose of this analysis.¹ A SAS program was designed to monitor seroconversion and the transmission of HIV within the couples. Two SAS data step procedures calculate HIV seroconversion and transmission rates for the entire follow-up period of the cohort. The investigator was also interested in computing seroconversion and transmission rates during specified time intervals: 1) during each 3-month follow-up interval, 2) during progressively longer periods (e.g, 0-6 months, 0-9 months, etc.) and 3) for specified combinations of these same three month intervals (e.g., from month 6 to month 12). The program consists of three macros implementing the three calculations described above. Total person months and number of seroconvertors are calculated by sex and for both sexes combined among at-risk (i.e., HIV-) subjects. Seroconversion rates are expressed as the number of HIV seroconvertors per 100 person-years of follow-up. Transmission rates are expressed as the number of HIV seroconvertors per 100 person-years of follow-up after eliminating seroconvertors in whom within-couple transmission could not be confirmed from the numerator of the rates. Confidence intervals for seroconversion rates are calculated using the GAMINV function in SAS to determine the upper and lower limits for the number of seroconvertors (which is assumed to follow a Poisson distribution), then divided by the total person months of follow-up. This program can be easily modified to calculate incidence rates of other outcomes and can accommodate variable follow-up intervals.

COHORT DATA SET

For all segments of this program which calculate seroconversion or transmission rates, the input data set to the initial DATA step is the cohort data set with one observation for each HIV- member of a couple. There are 5 variables in the data set (all date variables are SAS date values):

NUMSUJ= subject number
 FSTDATE= baseline visit date
 LVDATE= last visit date
 CJ= HIV status for male and female at baseline
 STDYSTAT= seroconversion status

NUMSUJ is a numeric variable which identifies both members of the discordant couple in the study. NUMSUJ values for eligible subjects are 5000 or greater.

FSTDATE is the baseline visit date when HIV discordant couple status was established for both members of the couple. This is the beginning of follow-up date.

LVDATE for seroconvertors is the visit date when HIV seroconversion was confirmed by serotesting. For nonseroconvertors in which one member of the couple died during follow-up, LVDATE is the last visit date when serotesting confirmed HIV seronegative status. Similarly, for nonseroconvertors in which both partners of the couple were alive as of the end of follow-up, LVDATE is the last visit date when serotesting was done for the HIV seronegative partner.

CJ is a character variable of length 2 which denotes HIV status of the male and female partners in the couple at baseline: "CJ". CJ are letters from the French word "CONJOINT" meaning spouse. C represents the male HIV status and J represents the female HIV status. CJ only has values "+-" or "-+" where + is for HIV seropositive and - is for HIV seronegative. The seronegative gender is the partner at-risk for HIV seroconversion.

STDYSTAT is a numeric variable of value 0-2.

0= nonseroconverter
 1= seroconverter from linked couple
 2=seroconverter from unlinked couple

SEROCONVERSION RATES

To calculate seroconversion rates for this cohort, the programming code first computes person-days of follow-up (PDAY) as the end of follow-up date minus the beginning of follow-up date (LVDATE-FSTDATE), for all at-risk HIV-subjects and separately for females (FEMPDAY) and males (MALPDAY). The CJ variable identifies whether the male or female partner is HIV seronegative at baseline. Person-days are summed over observations to accumulate total person-days. The cumulated variables output from this data set are TOTPDAY for all subjects, TFEMPDAY for females and TMALPDAY for males. Seroconvertors are identified via the STDYSTAT variable (STDYSTAT= 1 or 2) and variables for total number of seroconvertors (NUMCONV), female seroconvertors (NFEMCONV) and male seroconvertors (NMALCONV) are generated by the program. When processing the last record of the input data set, seroconversion rates for the cohort are computed by dividing total seroconvertors by total person days divided by 365.25 and multiplying by 100. Thus the seroconversion rate is expressed as the number of seroconvertors per 100 person-years of follow-up. Seroconversion rates for males and females are also computed and all rate variables along with the total seroconverter variables and total person day variables are output to a temporary data set.

```
proc sort data=newdata.serrate out=serrate;
  by numsuj; run;

data convrate;
  set serrate end=last;

  if _N_=1 then do;
    numconv=0; totpday=0; nfemconv=0; tfempday=0;
    nmalconv=0; tmalpday=0;
  end;
  pday=0; fempday=0; malpday=0;

  *** All subjects;
  pday=lvdate-fstdate;
  if pday=0 then delete;
  totpday = totpday + pday;

  if stdystat in (1,2) then numconv = numconv + 1;

  *** Female subjects;
  if cj='+-' then fempday=lvdate-fstdate;
  tfempday = tfempday + fempday;

  if (stdystat in (1,2) and cj='+-') then
    nfemconv= nfemconv+1;

  *** Male subjects;
  if cj='-+' then malpday=lvdate-fstdate;
  tmalpday = tmalpday + malpday;

  if (stdystat in (1,2) and cj='-+') then
    nmalconv = nmalconv + 1;

  if last then do;
    convrate=(numconv/(totpday/365.25))*100;
    femcrate= (nfemconv/(tfempday/365.25))*100;
    malcrate = (nmalconv/(tmalpday/365.25))*100;
    output;
  end;

  retain numconv nfemconv nmalconv totpday tfempday
    tmalpday ;

run;

proc print data=convrate noobs;
  var numconv totpday convrate nfemconv tfempday
    femcrate nmalconv tmalpday malcrate ;
  title1 'Seroconversion rates expressed per 100 person
    years of follow up';
run;
```

The second data step calculates 95% confidence intervals for the seroconversion rates. The program employs the known statistical relation between the cumulative distribution of a Poisson random variable and the Chi-square distribution, which in turn is a member of the gamma family of statistical distributions. In this case, the GAMINV(a,b) function in SAS returns the value of the mean of the Poisson variate that marks the cumulative probability "a" (in this program, 2.5%) of observing at most k-1 events when b=k observed events; or the cumulative probability "a" (in this program, 97.5%) of observing at least k events when b=k+1. Thus, the SAS statement "lo=GAMINV(0.025,5);" returns the lower 95% confidence limit for 5 observed events, whereas the statement "hi=GAMINV(0.975,6);" returns the corresponding upper 95% confidence limit. Next, the two boundaries computed using the procedure described above are divided by the total person days of follow-up (which is

assumed to be a constant with no random variability), divided by 365.25 and multiplied by 100 to obtain the 95% confidence boundaries of the seroconversion rate (per 100 person-years).

```
data conf;
  set convrate;

  *** all seroconvertors;
  lo=gaminv(.025,numconv);
  hi=gaminv(.975,numconv+1); *** # seroconvertors+1;
  rloi=(lo/(totpday/365.25))*100;
  rhii=(hi/(totpday/365.25))*100;

  *** male seroconvertors;
  mlo=gaminv(.025,nmalconv);
  mhi=gaminv(.975,nmalconv+1); ***# seroconvertors+1;
  mrloi=(mlo/(tmalpday/365.25))*100;
  mrhii=(mhi/(tmalpday/365.25))*100;

  *** female seroconvertors;
  flo=gaminv(.025,nfemconv);
  fhi=gaminv(.975,nfemconv+1); ***# seroconvertors+1;
  frloi=(flo/(tfempday/365.25))*100;
  frhii=(fhi/(tfempday/365.25))*100;
run;

proc print data=conf noobs;
  var lo hi rloi rhii flo fhi frloi frhii mlo mhi mrloi mrhii;
  title1 'Confidence intervals for # seroconvertors and
         seroconversion rate';
  title2 'Both sexes, male and female seroconvertors';
  title3 'Zambia discordant couple study';
run;
```

TRANSMISSION RATES

Calculation of transmission rates of HIV within the couple as indicated by seroconversion with confirmed epidemiological linkage by DNA sequencing is similar to the calculation of seroconversion rates. The difference between the current data step to calculate transmission rates and the prior data step for the calculation of seroconversion rates is that now the total count of seroconvertors includes only seroconvertors with the value of the variable STDYSTAT equal to 1 (seroconvertors in linked couples). Modifications are shown below:

```
if stdystat = 1 then numconv = numconv + 1;

if (stdystat = 1 and cj='-+') then nfemconv = nfemconv + 1;

if (stdystat = 1 and cj='-+') then nmalconv = nmalconv + 1;
```

RATES FOR 3-MONTH FOLLOW-UP INTERVALS

The first macro was designed to calculate seroconversion rates during each 3 month follow-up interval for at-risk HIV-subjects in the cohort. When the macro is invoked the macro program statement reads the value of the macro parameter NUMMON as a string value. The %LET statement with the %EVAL function converts NUMMON to a numeric integer value which for this cohort ranges in value from 1 to 17. Within this macro, the macro variable NUMMON is repeatedly multiplied by 3 generating 3 month integer values for the consecutive 3 month follow-up visit numbers. The program creates the variable LASTVMON as the nearest 3 month-visit value for the length of follow-up in

months using the ROUND function. PMON is the number of person-months accumulated for that subject within the 3 month follow-up interval of interest. If the value of LASTVMON is greater than NUMMON multiplied by 3 then the value of PMON equals 3. When LASTVMON equals NUMMON multiplied by 3 then the person months value for these subjects is the total length of follow-up in months minus the integer value for the prior 3 month visit. This provides a more accurate accumulation of follow-up time for subjects whose end of follow-up date may have been less than or greater than the 3 month visit for which we are calculating seroconversion rates since the prior 3 month follow-up visit. The cumulated variables output from this data set for total person months are TOTPMON for all subjects, TFEMPMON for females and TMALPMON for males. Seroconvertors are counted when STDYSTAT equals 1 or 2 and when the 3 month visit when seroconversion occurred (LASTVMON) equals the 3 month visit interval selected for the rate calculations (NUMMON multiplied by 3). Cumulated # of seroconvertors have the same names as before; total number of seroconvertors: NUMCONV, total female seroconvertors: NFEMCONV and total male seroconvertors: NMALCONV. When processing the last record of the input data set, seroconversion rates for the 3-month visit interval are computed by dividing total seroconvertors by total person months divided by 12 and multiplying by 100. The 3-month interval seroconversion rates are expressed as the number of seroconvertors per 100 person-years of follow-up. Three month visit interval seroconversion rates for males and females are also computed. All variables for rates, total # seroconvertors and total # person days are output to a temporary data set. Ninety-five percent confidence intervals for the seroconversion rates are calculated as before except total person months are divided by 12 because we are no longer using a measurement in person-days. The form delimiter option separates 3 month interval rates by asterisks on the printed output page instead of generating a new page for each new 3 month interval. Modifications for transmission rates are similar to the changes noted previously.

```
options formdlm='*';

%macro conv(nummon);
  data conv3mos;
    set serrate end=last;

    if (lvdate-fstdate)=0 then delete;

    %let nummon=%eval(&nummon);

    if _N_=1 then do;
      numconv=0; totpmon=0; nfemconv=0; tfempmon=0;
      nmalconv=0; tmalpmmon=0;
    end;
    pmmon=0; fempmmon=0; malpmmon=0;

    /*Calculates last 3 month visit attended by subject */

    lastvmmon=round(((lvdate-fstdate)/30.3)/3)*3;

    *** Checks for subjects with follow-up time rounding to
        0 months, for these subjects rounds up to the higher
        month visit;

    if lastvmmon=0 then put numsuj= stdystat= ;
    if lastvmmon=0 then lastvmmon=3;
```

```

*** All subjects;
if lastvmon >= %eval(&nummon*3) then do;
  if lastvmon > %eval(&nummon*3) then pmon=3;
  else if lastvmon = %eval(&nummon*3)
    then pmon=
      ((lvddate-fstdate)/30.3)-(%eval((&nummon*3)-3));
end;
totpmon = totpmon + pmon;

if stdystat in (1,2) and lastvmon = %eval(&nummon*3)
  then numconv = numconv + 1;

*** Female subjects;
if cj='-+' and lastvmon >= %eval(&nummon*3) then do;
  if lastvmon > %eval(&nummon*3) then fempmon=3;
  else if lastvmon = %eval(&nummon*3)
    then fempmon=
      ((lvddate-fstdate)/30.3)-(%eval((&nummon*3)-3));
end;
tfempmon = tfempmon + fempmon;

if stdystat in (1,2) and cj='-+'
  and lastvmon = %eval(&nummon*3)
  then nfemconv = nfemconv + 1;

*** Male subjects;
if cj='-+' and lastvmon >= %eval(&nummon*3) then do;
  if lastvmon > %eval(&nummon*3) then malpmon=3;
  else if lastvmon = %eval(&nummon*3)
    then malpmon=
      ((lvddate-fstdate)/30.3)-(%eval((&nummon*3)-3));
end;
tmalpmon = tmalpmon + malpmon;

if stdystat in (1,2) and cj='-+'
  and lastvmon = %eval(&nummon*3)
  then nmalconv = nmalconv + 1;

if last then do;
  convrate = (numconv/(totpmon/12))*100;
  femcrate = (nfemconv/(tfempmon/12))*100;
  malcrate = (nmalconv/(tmalpmon/12))*100;

  %let titlmon=%eval(&nummon*3);
  output;
end;

retain numconv totpmon nfemconv nmalconv
      tfempmon tmalpmon ;
run;

proc print data=conv3mos noobs;
var numconv totpmon convrate nfemconv tfempmon
    femcrate nmalconv tmalpmon malcrate;
title1 "Seroconversion rates expressed per 100 person
        years of follow up for &titlmon months";
title2 ' '; title3 ' '; title4 ' '; run;

/*** CONFIDENCE INTERVALS ***/
data conv3mos;
  set conv3mos;
  * all seroconvertors;
  lo=gaminv(.025,numconv);
  hi=gaminv(.975,numconv+1); *** # seroconvertors+1;
  rloi=(lo/(totpmon/12))*100;
  rhii=(hi/(totpmon/12))*100;

  * male seroconvertors;
  mlo=gaminv(.025,nmalconv);

```

```

mrloi=(mlo/(tmalpmon/12))*100;
mrhii=(mhi/(tmalpmon/12))*100;

* female seroconvertors;
flo=gaminv(.025,nfemconv);
fhi=gaminv(.975,nfemconv+1); *** # seroconvertors+1;
frloi=(flo/(tfempmon/12))*100;
frhii=(fhi/(tfempmon/12))*100;
run;

proc print data=conv3mos noobs;
var lo hi rloi rhii flo fhi frloi frhii mlo mhi mrloi mrhii;
title1 'Confidence intervals for # seroconvertors and
        seroconversion rate';
title2 'Both sexes, male and female seroconvertors';
title3 'Zambia discordant couple study';
title4 "&titlmon months";
run;
%mend conv;

%conv(1)
%conv(2) ..... %conv(17)

```

RATES FOR PROGRESSIVELY LONGER INTERVALS

The second macro was designed to calculate seroconversion rates during progressively longer periods (e.g. 0-3 months, 0-9 months, 0-12 months, etc.) for at-risk HIV- subjects in the cohort. Changes to the existing macro to achieve this task are described below. PMON is the number of person-months accumulated for each subject from baseline up to the 3 month follow-up visit of interest. An iterative DO loop is used to accumulate additional follow-up time to the value of PMON with successive 3 month intervals. The loop always begins with 1 and ends with the value of NUMMON. If the value of LASTVMON is greater than the index variable *i* multiplied by 3 then the value added to PMON equals 3. Otherwise when LASTVMON equals *i* multiplied by 3 then the amount of follow-up time added to PMON in months for these subjects is the total length of follow-up in months minus the integer value for the prior 3 month visit. Seroconvertors are counted when STDYSTAT equals 1 or 2 and when the 3 month visit when seroconversion occurred (LASTVMON) is between 0 and the 3 month visit interval selected for the rate calculations (NUMMON multiplied by 3).

```

%macro convr(nummon);
data conv3mon;
  set serrate end=last;
  if (lvddate-fstdate)=0 then delete;
  %let nummon=%eval(&nummon);

  if _N_=1 then do;
    numconv=0; totpmon=0; nfemconv=0; tfempmon=0;
    nmalconv=0; tmalpmon=0;
  end;
  pmon=0; fempmon=0; malpmon=0;

  /* Calculates last 3 month visit interval attended by
     subject */
  lastvmon=round(((lvddate-fstdate)/30.3)/3)*3;

  *** Checks for subjects with follow-up time rounding to
       0 months, for these subjects rounds up to the higher
       month visit;
  if lastvmon=0 then put numsuj= stdystat= ;
  if lastvmon=0 then lastvmon=3;

```

```

*** All subjects;
do i=1 to &nummon;
  if lastvmon >= i*3 then do;
    if lastvmon > i*3 then pmon=pmon + 3;
    else if lastvmon = i*3 then
      pmon=pmon + (((lvdte-fstdate)/30.3)-((i*3)-3));
    end;
  end;
  totpmon = totpmon + pmon;

  if stdystat in (1,2) and
    0 < lastvmon <= %eval(&nummon*3)
    then numconv = numconv + 1;

*** Female subjects;
do i=1 to &nummon;
  if cj='-+' and lastvmon >= i*3 then do;
    if lastvmon > i*3 then fempmon=fempmon + 3;
    else if lastvmon = i*3 then
      fempmon=fempmon + (((lvdte-fstdate)/30.3)-((i*3)-3));
    end;
  end;
  tfempmon = tfempmon + fempmon;

  if stdystat in (1,2) and cj='-+' and
    0 < lastvmon <= %eval(&nummon*3)
    then nfemconv = nfemconv + 1;

*** Male subjects;
do i=1 to &nummon;
  if cj='-+' and lastvmon >= i*3 then do;
    if lastvmon > i*3 then malpmon=malpmon + 3;
    else if lastvmon = i*3 then
      malpmon=malpmon + (((lvdte-fstdate)/30.3)-((i*3)-3));
    end;
  end;
  tmalpmon = tmalpmon + malpmon;

  if stdystat in (1,2) and cj='-+' and
    0 < lastvmon <= %eval(&nummon*3)
    then nmalconv = nmalconv + 1;

  if last then do;
    convrate = (numconv/(totpmon/12))*100;
    femcrate = (nfemconv/(tfempmon/12))*100;
    malcrate = (nmalconv/(tmalpmon/12))*100;
    %let titlmon=%eval(&nummon*3);
    output;
  end;

  retain numconv totpmon nfemconv nmalconv
    tfempmon tmalpmon ; run;

proc print data=conv3mon noobs;
var numconv totpmon convrate nfemconv tfempmon
femcrate nmalconv tmalpmon malcrate;
title1 "Seroconversion rates expressed per 100 person
years of follow up";
title2 "for up to and including &titlmon months";
title3 ' '; title4 ' '; run;

/*** CONFIDENCE INTERVALS ***/
data conf3mon;
set conv3mon;
* all seroconvertors;
lo=gaminv(.025,numconv);
hi=gaminv(.975,numconv+1); *** # seroconvertors+1;

```

```

rloi=(lo/(totpmon/12))*100;
rhii=(hi/(totpmon/12))*100;

* male seroconvertors;
mlo=gaminv(.025,nmalconv);
mhi=gaminv(.975,nmalconv+1); ** # seroconvertors+1;
mrloi=(mlo/(tmalpmon/12))*100;
mrhii=(mhi/(tmalpmon/12))*100;

* female seroconvertors;
flo=gaminv(.025,nfemconv);
fhi=gaminv(.975,nfemconv+1); ** # seroconvertors+1;
frloi=(flo/(tfempmon/12))*100;
frhii=(fhi/(tfempmon/12))*100;
run;

proc print data=conf3mon noobs;
var lo hi rloi rhii flo fhi frloi frhii mlo mhi mrloi mrhii;
title1 'Confidence intervals for # seroconvertors and
seroconversion rate';
title2 'Both sexes, male and female seroconvertors';
title3 'Zambia discordant couple study';
title4 "up to and including &titlmon months";
run;
%mend convr;
%convr(1) .... %convr(17)

```

RATES FOR SPECIFIC COMBINATIONS OF 3-MONTH FOLLOW-UP INTERVALS

The third macro was designed to calculate seroconversion rates for specified combinations of these same 3 month follow-up intervals (e.g. from month 6 to 12) for at-risk HIV-subjects in the cohort. Specific modifications to the existing macro for this purpose are explained in detail below. During invocation of the macro, the macro program statement reads the value of the macro parameters NUMMON and ENDMON as string values. The %LET statement with the %EVAL function converts NUMMON and ENDMON to numeric integer values which for this cohort ranges in value from 1 to 17. ENDMON can only be a number equal to or greater than the value of NUMMON. PMON is the number of person-months accumulated for each subject for selected visit month intervals. A DO loop iterates for values of i, the index variable, beginning with the macro variable NUMMON and ending with the macro variable ENDMON. Within this DO loop, follow-up time is added to the value of PMON with successive 3 month intervals. The index variable multiplied by 3 is compared to the value of the variable LASTVMON which is the nearest 3 month-visit value for the subject's entire length of follow-up time in months using the ROUND function. If the value of LASTVMON is greater than the index variable i multiplied by 3 then the value added to PMON equals 3. Otherwise when LASTVMON equals i multiplied by 3 then the amount of follow-up time added to PMON in months for these subjects is the total length of follow-up in months minus the integer value for the prior 3 month visit. Seroconvertors are counted when STDYSTAT equals 1 or 2 and when the 3 month visit when seroconversion occurred (LASTVMON) is between the macro variable NUMMON multiplied by 3 and the macro variable ENDMON multiplied by 3.

```

%macro convspec(nummon,endmon);
data conv_sel;
  set serrate end=last;
  if (lvdate-fstdate)=0 then delete;

  %let nummon=%eval(&nummon);
  %let endmon=%eval(&endmon);

  if _N_=1 then do;
    numconv=0; totpmon=0; nfemconv=0; tfempmon=0;
    nmalconv=0; tmalpmon=0;
  end;
  pmon=0; fempmon=0; malpmon=0;

  /* Calculates last 3 month visit interval attended by
  subject */
  lastvmon=round(((lvdate-fstdate)/30.3)/3)*3;

  *** Checks for subjects with follow-up time rounding to 0
  months, for these subjects rounds up to the higher
  month visit;
  if lastvmon=0 then put numsuj= stdystat= ;
  if lastvmon=0 then lastvmon=3;

  *** All subjects;
  do i=&nummon to &endmon;
    if lastvmon >= i*3 then do;
      if lastvmon > i*3 then pmon=pmon + 3;
      else if lastvmon = i*3 then
        pmon=pmon + (((lvdate-fstdate)/30.3)-((i*3)-3));
      end;
    end;
    totpmon = totpmon + pmon;

  if stdystat in (1,2) and
  %eval(&nummon*3)<=lastvmon<=%eval(&endmon*3)
  then numconv = numconv + 1;

  *** Female subjects;
  do i=&nummon to &endmon;
    if cj='-+' and lastvmon >= i*3 then do;
      if lastvmon > i*3 then fempmon=fempmon + 3;
      else if lastvmon = i*3 then
        fempmon=fempmon + (((lvdate-fstdate)/30.3)-((i*3)-3));
      end;
    end;
    tfempmon = tfempmon + fempmon;

  if stdystat in (1,2) and cj='-+' and
  %eval(&nummon*3) <= lastvmon <= %eval(&endmon*3)
  then nfemconv = nfemconv + 1;

  *** Male subjects;
  do i=&nummon to &endmon;
    if cj='-+' and lastvmon >= i*3 then do;
      if lastvmon > i*3 then malpmon=malpmon + 3;
      else if lastvmon = i*3 then
        malpmon=malpmon + (((lvdate-fstdate)/30.3)-((i*3)-3));
      end;
    end;
    tmalpmon = tmalpmon + malpmon;

  if stdystat in (1,2) and cj='-+' and
  %eval(&nummon*3) <= lastvmon <= %eval(&endmon*3)
  then nmalconv = nmalconv + 1;

  if last then do;
    convrate = (numconv/(totpmon/12))*100;
    femcrate = (nfemconv/(tfempmon/12))*100;
    malcrate = (nmalconv/(tmalpmon/12))*100;
  end;
end;

```

```

%let titlmon=%eval(&nummon*3);
%let titlend=%eval(&endmon*3);
output;
end;
retain numconv totpmon nfemconv nmalconv tfempmon
      tmalpmon ;
run;

proc print data=conv_sel noobs;
var numconv totpmon convrate nfemconv tfempmon
    femcrate nmalconv tmalpmon malcrate;
title1 "Seroconversion rates expressed per 100 person
        years follow up for &titlmon to &titlend months";
title2 ' '; title3 ' '; title4 ' '; run;

data conf_sel;
  set conv_sel;
  * all seroconvertors;
  lo=gaminv(.025,numconv);
  hi=gaminv(.975,numconv+1); *** # of serconvertors + 1;
  rloi=(lo/(totpmon/12))*100;
  rhii=(hi/(totpmon/12))*100;

  * male seroconvertors;
  mlo=gaminv(.025,nmalconv);
  mhi=gaminv(.975,nmalconv+1); ** # of seroconvertors+1;
  mrloi=(mlo/(tmalpmon/12))*100;
  mrhii=(mhi/(tmalpmon/12))*100;

  * female seroconvertors;
  flo=gaminv(.025,nfemconv);
  fhi=gaminv(.975,nfemconv+1); ** # of seroconvertors+1;
  frloi=(flo/(tfempmon/12))*100;
  frhii=(fhi/(tfempmon/12))*100;
run;

proc print data=conf_sel noobs;
var lo hi rloi rhii flo fhi frloi frhii mlo mhi mrloi mrhii;
title1 "Confidence intervals for # seroconvertors and
        seroconversion rate";
title2 "Both sexes, male and female seroconvertors";
title3 "Zambia discordant couple study";
title4 "&titlmon to &titlend months";
run;
%mend convspec;
%convspec(1,1)
%convspec(2,4)
%convspec(5,8)
%convspec(5,17)

```

CONCLUSION

Computing incidence rates, such as the seroconversion and transmission rates that are the epidemiologic measures of interest in this study, is an important programming aspect in the analysis of all follow-up studies in which new outcomes occur during an extended observation period. SAS provided an excellent work environment for data entry, data manipulations and other statistical analyses of predictors of seroconversion in this study, but did not provide specific support for the computation of incidence rates. Given the versatility of the SAS programming language and the availability of advanced statistical function, however, it was relatively easy to write the program presented in this paper which includes both rate calculation and statistical inference about rate estimates. This program can be easily modified to calculate incidence rates of other outcomes and can accommodate variable follow-up intervals. The program described in this paper addresses the important issue of

monitoring change in seroconversion or transmission rates for variable lengths of follow-up time since the induction of intervention programs consisting of HIV testing and counseling to encourage safer sex in HIV discordant couples.

REFERENCES

1. Meinzen-Derr J, Kautzman M, Haworth A, Zulu I, Trask S, Gao F, Allen S (2000), Self-report of condom use among cohabiting heterosexual discordant couples in Lusaka, Zambia: Validation with biological markers. Submitted for publication.
2. McKenna S, Muyinda G, Roth D, Mwali M, Ng'andu N, Myrick A, Luo C, Priddy F, Hall V, von Lieven A, Sabatino J, Mark K, Allen S (1997), Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS, 11 Suppl 1, S103-S110.
3. Allen S, Tice J, Van de Perre P, Serufilira A, Hudes E, Nsengumuremyi F, Bogaerts J, Lindan C, Hulley S (1992), Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. British Medical Journal, 304, 1605-1608.

SAS and SAS/STAT software are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.

Other brand and product names are registered trademarks or trademarks of their respective companies.

AUTHOR CONTACT INFORMATION

Ilene Brill
Department of Epidemiology and International Health
University of Alabama at Birmingham
Mortimer Jordan Hall, Room 108
1530 3rd Avenue South
Birmingham, AL 35294-2010
Work Phone: (205) 975-5359
Fax: (205) 975-2435
Email: ibrill@ms.soph.uab.edu